Valeant Pharmaceuticals International Inc. (NYSE:VRX)’s share price was down 4.5% during mid-day trading on Friday . The stock traded as low as $23.36 and last traded at $23.37, with a volume of 10,426,314 shares changing hands. The stock had previously closed at $24.48.

Several equities analysts have recently issued reports on VRX shares. BMO Capital Markets reiterated a “market perform” rating and issued a $66.00 price objective on shares of Valeant Pharmaceuticals International in a research note on Friday, March 25th. Morgan Stanley restated a “hold” rating and set a $39.00 target price on shares of Valeant Pharmaceuticals International in a research note on Monday, March 28th. Rodman & Renshaw restated a “buy” rating and set a $118.00 target price on shares of Valeant Pharmaceuticals International in a research note on Monday, March 28th. Mizuho restated a “sell” rating on shares of Valeant Pharmaceuticals International in a research note on Thursday, March 31st. Finally, Citigroup Inc. restated a “buy” rating on shares of Valeant Pharmaceuticals International in a research note on Friday, April 1st. Seven analysts have rated the stock with a sell rating, sixteen have given a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $65.05.

The stock’s market capitalization is $7.83 billion. The company has a 50 day moving average of $23.11 and a 200 day moving average of $47.79.

Valeant Pharmaceuticals International (NYSE:VRX) last issued its quarterly earnings results on Tuesday, June 7th. The specialty pharmaceutical company reported $1.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.37 by $0.10. The firm earned $2.37 billion during the quarter, compared to the consensus estimate of $2.34 billion. During the same quarter in the previous year, the business posted $2.36 EPS. The business’s revenue for the quarter was up 9.3% compared to the same quarter last year. Equities research analysts anticipate that Valeant Pharmaceuticals International Inc. will post $6.59 EPS for the current fiscal year.

In other news, CEO Joseph C. Papa purchased 202,000 shares of the stock in a transaction dated Friday, June 10th. The shares were bought at an average cost of $24.48 per share, for a total transaction of $4,944,960.00. Following the transaction, the chief executive officer now owns 2,442,199 shares in the company, valued at $59,785,031.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Several institutional investors have recently modified their holdings of VRX. Vanguard Group Inc. boosted its position in shares of Valeant Pharmaceuticals International by 8.0% in the fourth quarter. Vanguard Group Inc. now owns 4,440,755 shares of the specialty pharmaceutical company’s stock valued at $451,403,000 after buying an additional 330,079 shares during the period. I.G. Investment Management LTD. boosted its position in shares of Valeant Pharmaceuticals International by 31.0% in the fourth quarter. I.G. Investment Management LTD. now owns 1,328,610 shares of the specialty pharmaceutical company’s stock worth $135,033,000 after buying an additional 314,616 shares during the last quarter. Nicholas Co. Inc. WI boosted its position in shares of Valeant Pharmaceuticals International by 15.6% in the fourth quarter. Nicholas Co. Inc. WI now owns 1,586,925 shares of the specialty pharmaceutical company’s stock worth $161,310,000 after buying an additional 214,435 shares during the last quarter. BNP Paribas Arbitrage SA boosted its position in shares of Valeant Pharmaceuticals International by 253.0% in the fourth quarter. BNP Paribas Arbitrage SA now owns 284,308 shares of the specialty pharmaceutical company’s stock worth $28,900,000 after buying an additional 203,760 shares during the last quarter. Finally, Diamond Hill Capital Management Inc. boosted its position in shares of Valeant Pharmaceuticals International by 77.8% in the fourth quarter. Diamond Hill Capital Management Inc. now owns 301,374 shares of the specialty pharmaceutical company’s stock worth $30,635,000 after buying an additional 131,832 shares during the last quarter.

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.